The Latest Breaking News from Amgen

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

Amgen has surpassed the Nasdaq recently, and analysts are cautiously optimistic about its future potential.

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.

Amgen has outperformed the broader market over the past year, yet Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Amgen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.

The use of advanced technologies, growing demand for personalized medicines, and rising investments in R&D are boosting the biotech industry’s prospects. Given this backdrop, investors could consider buying quality biotech stocks: Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and ANI Pharmaceuticals (ANIP). Read on.